Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.43 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.43 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.43 |
| ▸ | GCGR | P47871 | 1/20 | 0.42 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7119605 | 0.80 | RPS6KA3 (0.45) | RAB9ANPC1TP53NPSR1MAPK14 | |
| SCHEMBL415765 | 0.80 | MAPK1 (0.47) | RAB9ANPC1MAPK13MAPK12MAPK11 | |
| SCHEMBL417139 | 0.79 | NISCH (0.45) | RAB9ANPC1MAPK13MAPK12MAPK11 | |
| SCHEMBL10022693 | 0.79 | RAB9A (0.46) | RAB9ANPC1TP53NPSR1MAPK13 | |
| SCHEMBL416642 | 0.76 | POLB (0.56) | RAB9ANPC1MAPK13MAPK12MAPK11 | |
| SCHEMBL823787 | 0.76 | MAPK13 (0.43) | RAB9ANPC1TP53MAPK13MAPK12 | |
| SCHEMBL2304276 | 0.76 | POLB (0.39) | RAB9ANPC1NISCHL3MBTL1POLB | |
| SCHEMBL418276 | 0.76 | HRH1 (0.49) | RAB9ANPC1MAPK13MAPK12MAPK11 | |
| SCHEMBL416435 | 0.75 | POLB (0.60) | RAB9ANPC1MAPK13MAPK12MAPK11 | |
| SCHEMBL420012 | 0.74 | MGAM (0.43) | RAB9ANPC1MAPK13MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120022083-A1 | SMALL MOLECULE MODULATORS OF CELL ADHESION | ADHEREX TECHNOLOGIES, INC. (CA) | 2012-01-26 | — | — | US | claimed |
| US-20090291967-A1 | SMALL MOLECULE MODULATORS OF CELL ADHESION | ADHEREX TECHNOLOGIES, INC. (CA) | 2009-11-26 | — | — | US | claimed |
| US-8865726-B2 | Substituted pyrazolo[1,5-a]pyrimidine compounds as mTOR inhibitors | ARRAY BIOPHARMA INC. (US) | 2014-10-21 | — | — | US | disclosed |
| US-20120178715-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2012-07-12 | — | — | US | disclosed |
| US-20120178715-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2012-07-12 | — | — | US | disclosed |
| US-20120022083-A1 | SMALL MOLECULE MODULATORS OF CELL ADHESION | ADHEREX TECHNOLOGIES, INC. (CA) | 2012-01-26 | — | — | US | disclosed |
| US-20120022083-A1 | SMALL MOLECULE MODULATORS OF CELL ADHESION | ADHEREX TECHNOLOGIES, INC. (CA) | 2012-01-26 | — | — | US | disclosed |
| US-20120022083-A1 | SMALL MOLECULE MODULATORS OF CELL ADHESION | ADHEREX TECHNOLOGIES, INC. (CA) | 2012-01-26 | — | — | US | disclosed |
| US-20090291967-A1 | SMALL MOLECULE MODULATORS OF CELL ADHESION | ADHEREX TECHNOLOGIES, INC. (CA) | 2009-11-26 | — | — | US | disclosed |
| US-20090291967-A1 | SMALL MOLECULE MODULATORS OF CELL ADHESION | ADHEREX TECHNOLOGIES, INC. (CA) | 2009-11-26 | — | — | US | disclosed |
| US-20090291967-A1 | SMALL MOLECULE MODULATORS OF CELL ADHESION | ADHEREX TECHNOLOGIES, INC. (CA) | 2009-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178715-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS | MTOR, RICTOR, EIF4EBP1 | RAB9A 637/4885NPC1 1685/4885TP53 419/4885 |
| US-20090291967-A1 | SMALL MOLECULE MODULATORS OF CELL ADHESION | CDH1, EPCAM, ICAM1 | RAB9A 100/4885NPC1 3435/4885TP53 285/4885 |
| US-20120022083-A1 | SMALL MOLECULE MODULATORS OF CELL ADHESION | CDH1, EPCAM, ICAM1 | RAB9A 100/4885NPC1 3435/4885TP53 285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.